Trust Signals
Evidence standard: Every confidence rating in this page is tied to a named evidence type. Speculative claims are labeled as such.
Last reviewed: May 29, 2026.
No financial relationship with any somatropin manufacturer or peptide vendor influences this content.
Key Takeaways
- Somatropin (recombinant HGH) has FDA approval backed by multi-decade RCT data for diagnosed GH deficiency; no GH-releasing peptide except tesamorelin has cleared a comparable regulatory bar.
- The mechanistic difference is fundamental: exogenous HGH bypasses the hypothalamic-pituitary axis entirely, while secretagogue peptides (sermorelin, CJC-1295, ipamorelin) act upstream and preserve somatostatin feedback.
- Tesamorelin is the only GHRH-class peptide with phase III RCT data showing a statistically significant reduction in visceral fat, and even those results are specific to HIV-associated lipodystrophy, not healthy adults.
- The FDA issued guidance in 2024 restricting CJC-1295 and ipamorelin from compounding, materially affecting legal access to those specific peptides in the US.
- For adults without a diagnosed GH deficiency, neither exogenous HGH nor GH-releasing peptides have RCT evidence of benefits that exceed optimized sleep, resistance training, and nutrition.
What Is the Core Difference Between HGH and Peptides?
Table of Contents
- How Each One Works: Mechanism with Specific Numbers
- Evidence Ledger: What the Trials Actually Show
- What Most Pages Get Wrong About This Comparison
- Is HGH or Peptide Use Legal?
- Safety Profiles Compared
- Honest Head-to-Head Table
- Why the Rules of Thumb Exist: The Chemistry
- Label and COA Literacy: Reading What You Actually Buy
- Who Actually Benefits? Candidacy by Clinical Context
- FAQ
- Sources
How Does Each One Work? Mechanism with Specific Numbers
Exogenous HGH (somatropin). Recombinant human somatropin is a 191-amino-acid single-chain polypeptide identical to pituitary-derived GH. Subcutaneous injection produces peak serum GH within roughly 3 to 5 hours and a half-life of approximately 2 to 4 hours (per FDA-reviewed pharmacokinetic data in somatropin prescribing information). It binds GH receptor dimers, primarily on hepatocytes, triggering JAK2-STAT5b phosphorylation and downstream IGF-1 gene transcription. Serum IGF-1 rises in a dose-proportional manner. Because the GH arrives exogenously, the hypothalamus and pituitary receive no instructional signal; they respond by downregulating endogenous GHRH and upregulating somatostatin, suppressing natural pulsatile GH release over time.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →GHRH analogues (sermorelin, CJC-1295, tesamorelin). These peptides bind the GHRH receptor (GHRHR) on anterior pituitary somatotrophs. Sermorelin is the first 29 amino acids of endogenous GHRH(1-44); tesamorelin is the full 44-amino-acid sequence stabilized by a trans-3-hexenoic acid conjugate. CJC-1295 adds a drug affinity complex (DAC) that binds albumin and extends the half-life from under 10 minutes (native GHRH) to an estimated 6 to 8 days, which produces a more chronic rather than pulsatile GH stimulus. The downstream signaling is cAMP-mediated, and crucially, somatostatin feedback remains functional, limiting GH amplitude.
GH secretagogues / GHRPs (ipamorelin, MK-677). These bind the ghrelin receptor (GHS-R1a), a distinct receptor on somatotrophs and hypothalamic neurons. Ipamorelin is a pentapeptide; MK-677 (ibutamoren) is a non-peptide oral secretagogue. GHS-R1a activation amplifies GH pulse amplitude and also reduces somatostatin tone via hypothalamic neurons. Ipamorelin is notable for relative selectivity, producing less cortisol and prolactin elevation than earlier GHRPs like GHRP-6, though head-to-head human RCT data are limited.
What the mechanism does NOT prove: The fact that these compounds raise GH or IGF-1 does not establish that this rise produces clinically meaningful improvements in body composition, performance, or longevity in healthy adults. Elevated IGF-1 is a biomarker change, not an outcome.
Evidence Ledger: What Do the Trials Actually Show?
| Compound and Claim | Best Evidence Type | Typical Sample Size / Duration | Effect Direction | Confidence |
|---|---|---|---|---|
| Somatropin reduces fat mass in adult GH deficiency | Multiple RCTs, systematic reviews | Hundreds of patients, 6 to 24 months | Positive (significant) | High |
| Somatropin increases lean mass in adult GH deficiency | RCTs, meta-analyses | Hundreds of patients | Positive (significant) | High |
| Somatropin improves body composition in healthy older adults (no GHD) | RCTs (Rudman 1990 NEJM and follow-up trials) | Dozens of patients, 6 months | Modest positive on lean mass and fat; no functional or longevity benefit confirmed | Moderate for body composition, Low for functional outcomes |
| Tesamorelin reduces visceral fat in HIV lipodystrophy | Phase III RCTs (Falutz et al., NEJM 2010) | Roughly 400 patients, 26 weeks | Positive (statistically significant vs placebo) | High for that specific population |
| Sermorelin raises GH and IGF-1 in adults | Small human trials (Walker et al. and others) | Dozens of patients | Positive on biomarker | Moderate for biomarker, Low for clinical outcomes |
| CJC-1295 raises IGF-1 in healthy adults | Single human PK/PD study (Teichman et al., JCEM 2006) | N=65 across dose cohorts | Positive (dose-dependent IGF-1 rise) | Moderate for biomarker, Very low for body composition outcomes |
| Ipamorelin produces selective GH release in humans | Small human pharmacology studies | Dozens of patients | Positive for GH pulse; lower cortisol/prolactin than GHRP-6 | Moderate for selectivity claim, Very low for clinical outcomes |
| MK-677 (oral secretagogue) improves lean mass | RCT (Nass et al., Ann Intern Med 2008; Svensson et al. data) | Dozens to low hundreds, up to 2 years | Modest positive on lean mass; no strength benefit confirmed in older adults | Moderate for lean mass biomarker |
What Most Pages Get Wrong About This Comparison
1. Treating a biomarker change as a clinical outcome. The majority of coverage of GH peptides focuses on IGF-1 levels rising after peptide administration. IGF-1 is a surrogate. The Rudman 1990 NEJM paper, often cited to argue HGH reverses aging, involved 12 men aged 61 to 81 over only 6 months and has never been replicated with functional or longevity endpoints. The authors themselves did not conclude that HGH reversed aging.
2. Ignoring the purity and stability problem. Research-grade peptides sold online in lyophilized powder form are not pharmaceutical-grade. Independent analyses by researchers and journalists have repeatedly found that commercially available research peptides vary substantially in actual peptide content and purity. A product labeled as ipamorelin at 5mg may contain degradation products, truncated sequences, or contaminants not visible without HPLC and mass spectrometry. Unlike a compounded pharmacy product, these carry no regulatory oversight.
3. Conflating "safer axis of action" with "proven safer." The argument that peptides are safer than HGH because they stay within the feedback axis is mechanistically plausible but not proven in long-term human trials. Combination protocols (CJC-1295 plus ipamorelin) are specifically designed to amplify GH pulse amplitude, and in that context the practical physiological difference from exogenous HGH at moderate doses narrows considerably.
4. Missing the 2024 FDA compounding restriction. Many pages still recommend CJC-1295 and ipamorelin as legal compounded alternatives to HGH. The FDA nominated both to its Category 2 list of bulk drug substances that raise significant safety concerns and may not be used in compounding, effective in 2024. This materially changes the legal landscape and is routinely omitted from older content.
Is HGH or Peptide Use Legal?
Somatropin is a Schedule III controlled substance under US federal law. It may be lawfully prescribed for a defined list of FDA-approved indications including adult-onset GH deficiency confirmed by provocative testing, pediatric short stature disorders, Turner syndrome, and several others. Off-label prescription for anti-aging or body composition optimization exists in a grey legal area; prescribing somatropin for anti-aging is specifically prohibited under the Anabolic Steroid Control Act as clarified by the FDA.
Among peptides, tesamorelin (Egrifta) is the only GHRH analogue with an approved NDA. Sermorelin previously had an approved NDA (Geref), which was withdrawn by the manufacturer; it now exists only as a compounded product. CJC-1295 and ipamorelin were placed on the FDA's list of bulk drug substances that may not be compounded following 2024 guidance. MK-677 is not approved and is not a peptide, classified as a small molecule investigational drug.
What Are the Real Safety Risks of Each?
Somatropin at supraphysiological doses carries documented risks including peripheral edema from sodium and water retention, carpal tunnel syndrome (reported in early dose-finding studies in adults), arthralgias, worsening glucose tolerance and frank insulin resistance, and potential for acromegalic features with long-term use above physiological replacement doses. The theoretical IGF-1-driven concern about cell proliferation and cancer promotion has not been definitively confirmed in adults receiving therapeutic GH replacement, but long-term pharmacovigilance studies remain ongoing.
GHRH-class peptides (sermorelin, CJC-1295) at doses producing physiological GH stimulation generally produce milder fluid retention and fewer metabolic side effects than supraphysiological somatropin. However, injection site reactions, headache, and flushing are reported. CJC-1295 with DAC, because it produces chronic rather than pulsatile GH elevation, may carry risks more similar to continuous HGH exposure than to pulsatile GHRH stimulation.
GHRPs (ipamorelin, GHRP-6) can stimulate cortisol and prolactin release. Ipamorelin is promoted as selective precisely because it causes less cortisol elevation than GHRP-6, though this selectivity claim rests on a limited human pharmacology dataset. GHRP-6 causes notable increases in appetite through ghrelin receptor activity, which may be undesirable depending on context.
Honest Head-to-Head Comparison
| Factor | Somatropin (HGH) | Sermorelin / GHRH analogues | Ipamorelin / GHRPs | Winner |
|---|---|---|---|---|
| RCT evidence base | Extensive (decades, large trials) | Limited small trials; tesamorelin is the exception | Minimal in humans | Somatropin |
| Regulatory approval (US) | FDA-approved (specific indications) | None currently (tesamorelin: HIV lipodystrophy only) | None | Somatropin |
| Preserves pituitary feedback axis | No | Yes | Yes (partial) | Peptides |
| Risk of supraphysiological GH at standard use | High (dose-dependent) | Lower at physiological doses | Lower at physiological doses | Peptides (with caveat) |
| Monthly cost (estimated, US) | High (several hundred to over $1,000) | Moderate when legally compounded (historically $100 to $300) | Varies; restricted access post-2024 | Peptides (historically) |
| Legal to use without Rx (US) | No | No (prescription required) | No | Tie (neither) |
| Oral availability | No (injectable only) | No (injectable; some intranasal formulations explored) | MK-677 is oral; peptide GHRPs are injectable | MK-677 if oral is priority |
| Purity guarantee in practice | High (pharmaceutical manufacturing) | Variable (compounding quality varies) | Low for research-grade; high if compounded | Somatropin |
| Evidence in healthy adults (no GHD) | Modest at best (Rudman-type data) | Very limited | Very limited | None convincing |
Why Do Stability and Formulation Rules Exist? The Chemistry
Why peptides must be stored cold and reconstituted carefully. Both somatropin and GH-releasing peptides are polypeptides held in biologically active conformation by non-covalent forces (hydrogen bonds, hydrophobic packing) and, in some cases, disulfide bridges. Heat and freeze-thaw cycling disrupt these forces and cause aggregation or denaturation. Denatured protein does not regain activity on cooling; the process is largely irreversible. Somatropin prescribing information specifies refrigeration at 2 to 8 degrees Celsius before reconstitution and use within a defined window after reconstitution because bacterial growth and further degradation accelerate once the lyophilized matrix is broken. Lyophilized (freeze-dried) peptides are more shelf-stable than solutions, but once reconstituted in bacteriostatic water, degradation begins via hydrolysis and oxidation.
Why bacteriostatic water matters. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and allows multi-draw use of a vial over days to weeks. Sterile water for injection contains no preservative and is intended for single use only. Using sterile water for multi-draw reconstitution of peptides introduces bacterial contamination risk; using bacteriostatic water for neonates is contraindicated because benzyl alcohol is toxic to newborns. The distinction is not arbitrary.
Why acidic co-formulation degrades some peptides. Some sermorelin formulations use an acidic diluent to maintain solubility; at very low pH, peptide bonds involving aspartate or asparagine can undergo acid hydrolysis over time. This is why mixing sermorelin with other peptides reconstituted in different pH diluents can accelerate degradation, a practical consequence competitors rarely explain.
How to Read a Label, COA, or Compounding Pharmacy Script
For a prescription compounded product: The label should name the active compound, dose in international units (IU) or micrograms, volume per dose, diluent identity, beyond-use date (BUD), and the prescribing physician's information. A legitimate compounding pharmacy will be registered with the state board of pharmacy. Ask for their USP 797 compliance status (sterile compounding standard).
For a COA (certificate of analysis) on any peptide product:
| COA Field | What to Look For | Red Flag |
|---|---|---|
| Identity confirmation | Mass spectrometry (MS) or HPLC with retention time match | UV absorbance only; no molecular weight reported |
| Purity | HPLC purity above 95% by area; method stated | Purity not stated or stated without method |
| Peptide content by weight | Stated as percentage of labeled weight | Absent; only nominal weight given |
| Endotoxin | LAL test result in EU/mg or EU/kg below USP limits for parenteral use | Not tested; "sterile" claimed without endotoxin data |
| Third-party testing | Accredited lab name and accreditation number on COA | COA issued by seller's own unaccredited facility |
| Lot number and date | Present and matches vial label | Generic COA not tied to a specific lot |
Dosing unit literacy. Somatropin is dosed in IU (international units) or milligrams; 1 mg of somatropin equals approximately 3 IU, though this conversion varies slightly by brand. GH-releasing peptides are typically dosed in micrograms (mcg), not milligrams. A vial labeled "5 mg" of a peptide reconstituted in 2 mL of bacteriostatic water yields a concentration of 2,500 mcg per mL. A 100 mcg dose from that vial equals 0.04 mL on an insulin syringe. Getting this math wrong by a factor of 10 is a common and serious user error.
Who Actually Benefits? Candidacy by Clinical Context
Clear evidence supports somatropin for: Adults with confirmed hypopituitarism or adult-onset GH deficiency diagnosed by provocative testing (insulin tolerance test or glucagon stimulation test). In this population, replacement to normal IGF-1 range improves body composition, bone density, lipid profiles, and quality of life with documented benefit in RCTs.
Clear evidence supports tesamorelin for: HIV-positive adults with antiretroviral-associated lipodystrophy showing excess visceral adipose tissue.
No strong evidence supports any GH intervention for: Anti-aging in otherwise healthy adults, general performance enhancement, or longevity extension. The 2003 position statement of the American Association of Clinical Endocrinologists and subsequent consensus documents have consistently concluded that GH therapy in healthy older adults is not recommended outside controlled trials.
The lifestyle comparison that most articles skip: A 2008 meta-analysis by Liu and colleagues (Annals of Internal Medicine) reviewed randomized trials of HGH in healthy adults and found modest increases in lean mass (roughly 2 kg) and decreases in fat mass but no improvement in strength or functional outcomes, alongside a significantly higher rate of adverse effects including edema, arthralgias, and carpal tunnel syndrome. Resistance training in the same age groups produces comparable or greater lean mass and strength changes with a far more favorable risk profile. This comparison is absent from most promotional content on either HGH or peptides.
Frequently Asked Questions
What is the core difference between HGH and growth hormone peptides?
Recombinant HGH (somatropin) directly replaces the hormone itself, producing a predictable, dose-proportional rise in IGF-1. Growth hormone secretagogue peptides such as sermorelin, CJC-1295, and ipamorelin instead stimulate the pituitary to release its own stored GH, so the axis remains under physiological feedback control and pulse amplitude is preserved rather than overridden.
Which has stronger clinical evidence: HGH or GH-releasing peptides?
HGH (somatropin) has the stronger evidence by a wide margin. Multiple large randomized controlled trials and decades of FDA-approved use in GH-deficient adults and children underpin its efficacy and safety profile. GH-releasing peptides have mostly small, short-duration human trials; sermorelin has the most human data among peptides, but the trial sizes and follow-up durations are far smaller than the somatropin evidence base.
Is HGH legal to use without a prescription?
No. Somatropin is a Schedule III controlled substance in the United States and may legally be prescribed only for specific FDA-approved indications including diagnosed adult-onset GH deficiency, Turner syndrome, and Prader-Willi syndrome. Off-label prescribing for anti-aging or body composition is legally restricted.
Are GH-releasing peptides like CJC-1295 and ipamorelin FDA-approved?
No currently available growth hormone secretagogue peptide is FDA-approved for clinical use in the United States as of 2025. The FDA placed CJC-1295 and ipamorelin on its list of bulk drug substances that may not be compounded in 2024, significantly restricting their availability through compounding pharmacies. Sermorelin is the one exception with prior approved status, though it lost its original NDA and now exists only as a compounded product.
What does sermorelin actually do mechanistically?
Sermorelin is a 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH) that binds the GHRH receptor on somatotroph cells of the anterior pituitary. This triggers cAMP-mediated signaling, GH synthesis, and pulsatile secretion. Because sermorelin acts upstream, GH release remains subject to somatostatin negative feedback, limiting supraphysiological GH elevations.
How do the costs of HGH and peptides compare?
Brand-name somatropin typically costs several hundred to over a thousand US dollars per month at body-composition doses without insurance. Compounded sermorelin historically ran roughly 100 to 300 USD per month, though recent FDA compounding restrictions have reduced availability. Research-grade peptides sold online are unregulated and purity is not guaranteed.
What are the main safety risks of exogenous HGH?
The most clinically documented risks of supraphysiological somatropin use include fluid retention, carpal tunnel syndrome, arthralgia, insulin resistance and worsening of glucose tolerance, and acromegalic features with long-term excess dosing. There is also a theoretical concern about IGF-1-driven cell proliferation and malignancy risk, though causation in adults at therapeutic doses has not been definitively established in RCTs.
Can peptides cause the same side effects as HGH?
At doses producing physiologically pulsatile GH release, secretagogue peptides generally cause fewer and milder side effects than supraphysiological HGH injection. However, high-dose or combination regimens can push IGF-1 above the normal range and carry risks similar to exogenous HGH. Ipamorelin specifically can elevate cortisol and prolactin, though this appears less pronounced than with older GHRPs like GHRP-6.
What does tesamorelin tell us that other peptides do not?
Tesamorelin (Egrifta) is the only GHRH analogue peptide with full FDA approval, specifically for HIV-associated lipodystrophy. Phase III RCTs (Falutz et al., NEJM 2010) showed statistically significant reductions in visceral adipose tissue vs placebo, providing proof-of-concept that GHRH-class peptides can produce measurable body composition changes. The patient population does not generalize to healthy adults.
How should I read a certificate of analysis (COA) for a peptide product?
Check for: identity confirmation by HPLC or mass spectrometry, purity above 95% by HPLC with the method stated, peptide content by weight, endotoxin testing by LAL assay, and a third-party accredited lab name with accreditation number. A COA from the seller's own unaccredited lab is not independently verified.
Does WADA ban both HGH and GH-releasing peptides?
Yes. The World Anti-Doping Agency prohibits somatropin and all GH-releasing factors including GHRH analogues (sermorelin, CJC-1295, tesamorelin), GH secretagogues